Project Grant R01CA308383
Award Date 8/5/26
Completion Date 7/31/31
Dollars Obligated $611K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Lexington, KY 40506, USA
Similar Awards
- The National Cancer Institute awarded Michigan State University Henry Ford Health+Michigan State University Health Sciences $309,874 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and test a fully asynchronous digital intervention for reducing alcohol misuse in adolescent and young adult cancer survivors. The project adapts TRAC-AYA (Tracking and Reducing Alcohol Consumption in AYAs), a technology-based intervention previously developed...
- The National Cancer Institute awarded The University of Kentucky Research Foundation $281,820 on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to plan a future intervention trial improving clinical trial education and enrollment for cancer patients. The planning grant supports development of an intervention designed to address persistently low cancer trial enrollment rates in the United States. The award funds preparatory work for a future randomized...
- The National Cancer Institute awarded The Research Foundation For The State University of New York $467,581 on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to support a mixed-methods ecological momentary assessment study examining substance use behaviors and underlying socioecological drivers among young adult cancer survivors in early survivorship. The research identifies mechanisms of substance use—including tobacco, alcohol, cannabis, illicit drugs, and...
- The National Cancer Institute awarded The Ohio State University $647,762 on July 14, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to optimize social media messages targeting young adult women about breast cancer risk from alcohol consumption. The funded research combines self-report and psychophysiological measures to identify optimal features of co-created social media messages communicating breast cancer risk from alcohol consumption and determine whether persuasive effects...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $177,500 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to adapt and evaluate a community navigator-led tobacco cessation intervention for cancer patients experiencing food insecurity. The project, titled QUITTRACK, addresses the elevated rate of tobacco dependence among food-insecure cancer patients—44 percent of cancer patients who smoke experience food insecurity,...
- The National Institutes of Health National Cancer Institute awarded the Sloan-Kettering Institute For Cancer Research $731,503 on June 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a randomized controlled trial of brief behavioral activation for older adult cancer survivors. The research addresses depression among cancer survivors aged 65 and older, a population expected to comprise 73 percent of all cancer survivors by 2040, with up to 35 percent...
- Federal Grant Award Summary The National Cancer Institute awarded a $164,484 Project Grant to The University of Kentucky Research Foundation on August 11, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393). This award supports a research initiative focused on developing and evaluating health communications targeting adults who smoke nondaily (ASN)—a population representing approximately one-third of current adult cigarette smokers in the United States yet demonstrating...
- The National Cancer Institute awarded $415,257 to the University of Virginia on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop a comprehensive intervention addressing financial toxicity among cancer survivors and caregivers. The award funds a two-year project (July 1, 2026 through June 30, 2028) performed in Charlottesville, Virginia. The intervention will address all domains of financial toxicity—material burden, psychosocial distress, and coping...
- The National Cancer Institute awarded Washington State University $560,858 on July 21, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a randomized controlled trial evaluating a remote telehealth intervention combining varenicline and app-based contingency management for rural smokers with alcohol use disorder. The trial will enroll 192 rural smokers seeking smoking cessation treatment and living with an alcohol use disorder. Participants will be...
- The National Cancer Institute awarded The MGH Institute of Health Professions, Inc. $696,498 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and optimize a multicomponent intervention for improving functional recovery and participation in life roles among breast cancer survivors. The research uses the Multiphase Optimization Strategy (MOST) framework to systematically test three remotely delivered intervention components: priority elicitation to...